

LETTERS

Plasmodium knowlesi infection imported to Germany, January 2013

A Bart (a.bart@amc.nl)¹, J J van Hellemond², P J van Genderen³, T Van Gool¹

1. Dept. Medical Microbiology, Section Parasitology, Academic Medical Center, Amsterdam, the Netherlands

2. Dept. Medical Microbiology and Infectious Diseases, Erasmus University Medical Center and Harbor Hospital, Rotterdam, the Netherlands

3. Institute for Tropical Diseases, Harbour Hospital, Rotterdam, the Netherlands

Citation style for this article:

Bart A, van Hellemond JJ, van Genderen PJ, Van Gool T. *Plasmodium knowlesi* infection imported to Germany, January 2013. *Euro Surveill.* 2013;18(44):pii=20619.

Available online: <http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=20619>

Article submitted on 23 October 2013 / published on 31 October 2013

To the editor: We read with great interest the article by Orth et al. [1] in *Eurosurveillance* on a recent case of imported *Plasmodium knowlesi* infection in Germany. This case nicely illustrates the pivotal role of microscopy on thick and thin blood films by experienced microscopists for malaria diagnosis. The statement in the discussion section that only five cases imported to Europe have been published so far, underestimates the occurrence of this infection. Two more cases imported to the Netherlands have been described previously [2,3].

One case was a migrant worker from Malayan Borneo, positive in microscopy with 2% infected erythrocytes. The rapid BinaxNOW Malaria Test was positive for the pan-malarial aldolase band but negative for *P. falciparum* histidine-rich protein 2 (HRP-2). Retrospective analysis of the initial sample also showed positive results in the *P. falciparum*-specific lactate dehydrogenase (LDH) and pan-malarial LDH in the OptiMAL Rapid Malaria Test (DiaMed, Cressier, Switzerland). This patient was successfully treated with oral chloroquine for three days [2].

The other patient was a tourist who also visited Malayan Borneo and participated in a two-day jungle trek. At presentation, this case had a low parasitaemia (0.0005%) with microscopy and negative reactions for both HRP-2 and aldolase in the BinaxNOW Malaria Test. The patient was successfully treated with malarone, a combination of atovaquone and proguanil [3]. Both cases were confirmed as *P. knowlesi* infections by molecular methods after treatment had been started.

We agree with Orth et al that physicians should be aware of the possibility of imported *P. knowlesi* infections in travellers. This is particularly relevant, as *P. knowlesi* with its 24-hour replication cycle can result in a high parasitaemia and severe, life-threatening disease. It is safe to assume that the geographic range of

P. knowlesi comprises all countries in south-east Asia, including the south of China.

Moreover, not only clinicians, but also laboratory personnel, traditionally only trained to identify the four more frequently observed *Plasmodium* species, *P. falciparum*, *P. vivax*, *P. ovale* and *P. malariae*, should be aware of this infection and its diagnostic challenges. *P. knowlesi* is morphologically very similar to *P. malariae* but can also be confused with *P. falciparum* in microscopy. As illustrated by the two cases described above, *P. knowlesi* infection causes variable results with commercially available rapid diagnostic tests, which do not seem to be reliable for diagnosis of *P. knowlesi* [3,4]. Although rapid diagnostic tests can complement microscopic diagnosis, they cannot replace microscopy, especially in patients with low parasite loads. For patients suspected of *P. knowlesi* infection, confirmation can be obtained either by specific PCR or by sequence analysis of generic *Plasmodium* PCR products, which are available in most specialised centres in Europe. While such confirmation is in progress, treatment should be installed based on positive blood smear results. From literature and our experience, it seems that oral treatment regimens suited for uncomplicated *P. malariae* and *P. falciparum* are also effective in clearing mild *P. knowlesi* infections, since resistance to antimalarial drugs has not been observed yet [5]. For more severe and complicated *P. knowlesi* infections, parenteral treatments associated with short parasite clearance times, such as artesunate, seem preferable.

References

1. Orth H, Jensen BO, Holtfreter MC, Kocheril SJ, Mallach S, MacKenzie C, et al. *Plasmodium knowlesi* infection imported to Germany, January 2013. *Euro Surveill.* 2013;18: (40):pii=20603. Available from: <http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=20603> PMID:24128698
2. van Hellemond JJ, Rutten M, Koelewijn R, Zeeman AM, Verweij JJ, Wismans PJ, et al. Human *Plasmodium knowlesi* infection detected by rapid diagnostic tests for malaria. *Emerg*

- Infect Dis. 2009;15(9):1478-80. <http://dx.doi.org/10.3201/eid1509.090358>
PMid:19788819. PMCid:PMC2819855.
3. Link L, Bart A, Verhaar N, van Gool T, Pronk M, Scharnhorst V. Molecular detection of *Plasmodium knowlesi* in a Dutch traveler by real-time PCR. *J Clin Microbiol.* 2012;50(7):2523-4. <http://dx.doi.org/10.1128/JCM.06859-11>
PMid:22573596. PMCid:PMC3405625.
 4. Barber BE, William T, Grigg MJ, Piera K, Yeo TW, Anstey NM. Evaluation of the sensitivity of a pLDH-based and an aldolase-based rapid diagnostic test for diagnosis of uncomplicated and severe malaria caused by PCR-confirmed *Plasmodium knowlesi*, *Plasmodium falciparum*, and *Plasmodium vivax*. *J Clin Microbiol.* 2013;51(4):1118-23. <http://dx.doi.org/10.1128/JCM.03285-12>
PMid:23345297. PMCid:PMC3666806.
 5. Kantele A, Jokiranta TS. Review of cases with the emerging fifth human malaria parasite, *Plasmodium knowlesi*. *Clin Infect Dis.* 2011;52(11):1356-62. <http://dx.doi.org/10.1093/cid/cir180>
PMid:21596677